Factors affecting intrapatient liver and mediastinal blood pool super(18)F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma
Purpose: The aim of our study was to assess the intrapatient variability of 2-deoxy-2-( super(18)F)-fluoro-D-glucose ( super(18)F-FDG) uptake in the liver and in the mediastinum among patients with Hodgkin's lymphoma (HL) treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarba...
Gespeichert in:
| Veröffentlicht in: | European journal of nuclear medicine and molecular imaging 2014-06, Vol.41 (6), p.1123-1132 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1132 |
|---|---|
| container_issue | 6 |
| container_start_page | 1123 |
| container_title | European journal of nuclear medicine and molecular imaging |
| container_volume | 41 |
| creator | Chiaravalloti, Agostino Danieli, Roberta Abbatiello, Paolo Pietro, Barbara Travascio, Laura Cantonetti, Maria Guazzaroni, Manlio Orlacchio, Antonio Simonetti, Giovanni Schillaci, Orazio |
| description | Purpose: The aim of our study was to assess the intrapatient variability of 2-deoxy-2-( super(18)F)-fluoro-D-glucose ( super(18)F-FDG) uptake in the liver and in the mediastinum among patients with Hodgkin's lymphoma (HL) treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy (CHT). Methods: The study included 68 patients (30 men, 38 women; mean age 32 plus or minus 11 years) with biopsy-proven HL. According to Ann Arbor criteria, 6 were stage I, 34 were stage II, 12 were stage 3 and 16 were stage 4. All of them underwent a baseline (PET0) and an interim (PET2) super(18)F-FDG whole-body positron emission tomography (PET)/CT. All patients were treated after PET0 with two ABVD cycles for 2 months that ended 15 plus or minus 5 days prior to the PET2 examination. All patients were further evaluated 15 plus or minus 6 days after four additional ABVD cycles (PET6). None of the patients presented a serum glucose level higher than 107 mg/dl. The mean and maximum standardized uptake values (SUV) of the liver and mediastinum were calculated using the same standard protocol for PET0, PET2 and PET6, respectively. Data were examined by means of the Wilcoxon matched pairs test and linear regression analysis. Results: The main results of our study were an increased liver SUV sub(mean) in PET2 (1.76 plus or minus 0.35) as compared with that of PET0 (1.57 plus or minus 0.31; p |
| doi_str_mv | 10.1007/s00259-014-2703-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_1524414455</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1524414455</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_15244144553</originalsourceid><addsrcrecordid>eNqVjU1OwzAQRi0EEuXnAOxmR1kE7DQhyRIooQdAbKshnqSmjh08TqVyGa7aICH2rL6nT096QlwpeaukLO5YyjSvEqmyJC3kIpFHYqbuVZUUsqyO_7iQp-KM-UNKVaZlNRPfNTbRBwZsW2qicR0YFwMOGA25CNbsKAA6DT1pgzwZaOHdeq9h8N4CjwOFuSpv6qRevgDHycWgzRdpGIeIW4Id2pGg2aDriEGP4afy8Pi2nD7qfdzQ1NtPXVh53W2Nu2aw-37Y-B4vxEmLlunyd8_FvH5-fVolQ_CfI3Fc94YbshYd-ZHXKk-zTGVZni_-oR4AEMlmaQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1524414455</pqid></control><display><type>article</type><title>Factors affecting intrapatient liver and mediastinal blood pool super(18)F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma</title><source>Springer Nature - Complete Springer Journals</source><creator>Chiaravalloti, Agostino ; Danieli, Roberta ; Abbatiello, Paolo ; Pietro, Barbara ; Travascio, Laura ; Cantonetti, Maria ; Guazzaroni, Manlio ; Orlacchio, Antonio ; Simonetti, Giovanni ; Schillaci, Orazio</creator><creatorcontrib>Chiaravalloti, Agostino ; Danieli, Roberta ; Abbatiello, Paolo ; Pietro, Barbara ; Travascio, Laura ; Cantonetti, Maria ; Guazzaroni, Manlio ; Orlacchio, Antonio ; Simonetti, Giovanni ; Schillaci, Orazio</creatorcontrib><description>Purpose: The aim of our study was to assess the intrapatient variability of 2-deoxy-2-( super(18)F)-fluoro-D-glucose ( super(18)F-FDG) uptake in the liver and in the mediastinum among patients with Hodgkin's lymphoma (HL) treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy (CHT). Methods: The study included 68 patients (30 men, 38 women; mean age 32 plus or minus 11 years) with biopsy-proven HL. According to Ann Arbor criteria, 6 were stage I, 34 were stage II, 12 were stage 3 and 16 were stage 4. All of them underwent a baseline (PET0) and an interim (PET2) super(18)F-FDG whole-body positron emission tomography (PET)/CT. All patients were treated after PET0 with two ABVD cycles for 2 months that ended 15 plus or minus 5 days prior to the PET2 examination. All patients were further evaluated 15 plus or minus 6 days after four additional ABVD cycles (PET6). None of the patients presented a serum glucose level higher than 107 mg/dl. The mean and maximum standardized uptake values (SUV) of the liver and mediastinum were calculated using the same standard protocol for PET0, PET2 and PET6, respectively. Data were examined by means of the Wilcoxon matched pairs test and linear regression analysis. Results: The main results of our study were an increased liver SUV sub(mean) in PET2 (1.76 plus or minus 0.35) as compared with that of PET0 (1.57 plus or minus 0.31; p<0.0001) and PET6 (1.69 plus or minus 0.28; p=0.0407). The same results were obtained when considering liver SUV sub(max) in PET2 (3.13 plus or minus 0.67) as compared with that of PET0 (2.82 plus or minus 0.64; p<0.0001) and PET6 (2.96 plus or minus 0.52; p=0.0105). No significant differences were obtained when comparing mediastinum SUV sub(mean) and SUV sub(max) in PET0, PET2 and PET6 (p>0.05). Another finding is a relationship in PET0 between liver SUV sub(mean) and SUV sub(max) with the stage, which was lower in those patients with advanced disease (r super(2)=0.1456 and p=0.0013 for SUV sub(mean) and r super(2)=0.1277 and p=0.0028 for SUV sub(max)). Conclusion: The results of our study suggest that liver super(18)F-FDG uptake is variable in patients with HL during the CHT treatment and the disease course and should be considered carefully when used to define the response to therapy in the interim PET in HL.</description><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-014-2703-0</identifier><language>eng</language><ispartof>European journal of nuclear medicine and molecular imaging, 2014-06, Vol.41 (6), p.1123-1132</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Chiaravalloti, Agostino</creatorcontrib><creatorcontrib>Danieli, Roberta</creatorcontrib><creatorcontrib>Abbatiello, Paolo</creatorcontrib><creatorcontrib>Pietro, Barbara</creatorcontrib><creatorcontrib>Travascio, Laura</creatorcontrib><creatorcontrib>Cantonetti, Maria</creatorcontrib><creatorcontrib>Guazzaroni, Manlio</creatorcontrib><creatorcontrib>Orlacchio, Antonio</creatorcontrib><creatorcontrib>Simonetti, Giovanni</creatorcontrib><creatorcontrib>Schillaci, Orazio</creatorcontrib><title>Factors affecting intrapatient liver and mediastinal blood pool super(18)F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma</title><title>European journal of nuclear medicine and molecular imaging</title><description>Purpose: The aim of our study was to assess the intrapatient variability of 2-deoxy-2-( super(18)F)-fluoro-D-glucose ( super(18)F-FDG) uptake in the liver and in the mediastinum among patients with Hodgkin's lymphoma (HL) treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy (CHT). Methods: The study included 68 patients (30 men, 38 women; mean age 32 plus or minus 11 years) with biopsy-proven HL. According to Ann Arbor criteria, 6 were stage I, 34 were stage II, 12 were stage 3 and 16 were stage 4. All of them underwent a baseline (PET0) and an interim (PET2) super(18)F-FDG whole-body positron emission tomography (PET)/CT. All patients were treated after PET0 with two ABVD cycles for 2 months that ended 15 plus or minus 5 days prior to the PET2 examination. All patients were further evaluated 15 plus or minus 6 days after four additional ABVD cycles (PET6). None of the patients presented a serum glucose level higher than 107 mg/dl. The mean and maximum standardized uptake values (SUV) of the liver and mediastinum were calculated using the same standard protocol for PET0, PET2 and PET6, respectively. Data were examined by means of the Wilcoxon matched pairs test and linear regression analysis. Results: The main results of our study were an increased liver SUV sub(mean) in PET2 (1.76 plus or minus 0.35) as compared with that of PET0 (1.57 plus or minus 0.31; p<0.0001) and PET6 (1.69 plus or minus 0.28; p=0.0407). The same results were obtained when considering liver SUV sub(max) in PET2 (3.13 plus or minus 0.67) as compared with that of PET0 (2.82 plus or minus 0.64; p<0.0001) and PET6 (2.96 plus or minus 0.52; p=0.0105). No significant differences were obtained when comparing mediastinum SUV sub(mean) and SUV sub(max) in PET0, PET2 and PET6 (p>0.05). Another finding is a relationship in PET0 between liver SUV sub(mean) and SUV sub(max) with the stage, which was lower in those patients with advanced disease (r super(2)=0.1456 and p=0.0013 for SUV sub(mean) and r super(2)=0.1277 and p=0.0028 for SUV sub(max)). Conclusion: The results of our study suggest that liver super(18)F-FDG uptake is variable in patients with HL during the CHT treatment and the disease course and should be considered carefully when used to define the response to therapy in the interim PET in HL.</description><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNqVjU1OwzAQRi0EEuXnAOxmR1kE7DQhyRIooQdAbKshnqSmjh08TqVyGa7aICH2rL6nT096QlwpeaukLO5YyjSvEqmyJC3kIpFHYqbuVZUUsqyO_7iQp-KM-UNKVaZlNRPfNTbRBwZsW2qicR0YFwMOGA25CNbsKAA6DT1pgzwZaOHdeq9h8N4CjwOFuSpv6qRevgDHycWgzRdpGIeIW4Id2pGg2aDriEGP4afy8Pi2nD7qfdzQ1NtPXVh53W2Nu2aw-37Y-B4vxEmLlunyd8_FvH5-fVolQ_CfI3Fc94YbshYd-ZHXKk-zTGVZni_-oR4AEMlmaQ</recordid><startdate>20140601</startdate><enddate>20140601</enddate><creator>Chiaravalloti, Agostino</creator><creator>Danieli, Roberta</creator><creator>Abbatiello, Paolo</creator><creator>Pietro, Barbara</creator><creator>Travascio, Laura</creator><creator>Cantonetti, Maria</creator><creator>Guazzaroni, Manlio</creator><creator>Orlacchio, Antonio</creator><creator>Simonetti, Giovanni</creator><creator>Schillaci, Orazio</creator><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20140601</creationdate><title>Factors affecting intrapatient liver and mediastinal blood pool super(18)F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma</title><author>Chiaravalloti, Agostino ; Danieli, Roberta ; Abbatiello, Paolo ; Pietro, Barbara ; Travascio, Laura ; Cantonetti, Maria ; Guazzaroni, Manlio ; Orlacchio, Antonio ; Simonetti, Giovanni ; Schillaci, Orazio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_15244144553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chiaravalloti, Agostino</creatorcontrib><creatorcontrib>Danieli, Roberta</creatorcontrib><creatorcontrib>Abbatiello, Paolo</creatorcontrib><creatorcontrib>Pietro, Barbara</creatorcontrib><creatorcontrib>Travascio, Laura</creatorcontrib><creatorcontrib>Cantonetti, Maria</creatorcontrib><creatorcontrib>Guazzaroni, Manlio</creatorcontrib><creatorcontrib>Orlacchio, Antonio</creatorcontrib><creatorcontrib>Simonetti, Giovanni</creatorcontrib><creatorcontrib>Schillaci, Orazio</creatorcontrib><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chiaravalloti, Agostino</au><au>Danieli, Roberta</au><au>Abbatiello, Paolo</au><au>Pietro, Barbara</au><au>Travascio, Laura</au><au>Cantonetti, Maria</au><au>Guazzaroni, Manlio</au><au>Orlacchio, Antonio</au><au>Simonetti, Giovanni</au><au>Schillaci, Orazio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Factors affecting intrapatient liver and mediastinal blood pool super(18)F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><date>2014-06-01</date><risdate>2014</risdate><volume>41</volume><issue>6</issue><spage>1123</spage><epage>1132</epage><pages>1123-1132</pages><issn>1619-7070</issn><eissn>1619-7089</eissn><abstract>Purpose: The aim of our study was to assess the intrapatient variability of 2-deoxy-2-( super(18)F)-fluoro-D-glucose ( super(18)F-FDG) uptake in the liver and in the mediastinum among patients with Hodgkin's lymphoma (HL) treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy (CHT). Methods: The study included 68 patients (30 men, 38 women; mean age 32 plus or minus 11 years) with biopsy-proven HL. According to Ann Arbor criteria, 6 were stage I, 34 were stage II, 12 were stage 3 and 16 were stage 4. All of them underwent a baseline (PET0) and an interim (PET2) super(18)F-FDG whole-body positron emission tomography (PET)/CT. All patients were treated after PET0 with two ABVD cycles for 2 months that ended 15 plus or minus 5 days prior to the PET2 examination. All patients were further evaluated 15 plus or minus 6 days after four additional ABVD cycles (PET6). None of the patients presented a serum glucose level higher than 107 mg/dl. The mean and maximum standardized uptake values (SUV) of the liver and mediastinum were calculated using the same standard protocol for PET0, PET2 and PET6, respectively. Data were examined by means of the Wilcoxon matched pairs test and linear regression analysis. Results: The main results of our study were an increased liver SUV sub(mean) in PET2 (1.76 plus or minus 0.35) as compared with that of PET0 (1.57 plus or minus 0.31; p<0.0001) and PET6 (1.69 plus or minus 0.28; p=0.0407). The same results were obtained when considering liver SUV sub(max) in PET2 (3.13 plus or minus 0.67) as compared with that of PET0 (2.82 plus or minus 0.64; p<0.0001) and PET6 (2.96 plus or minus 0.52; p=0.0105). No significant differences were obtained when comparing mediastinum SUV sub(mean) and SUV sub(max) in PET0, PET2 and PET6 (p>0.05). Another finding is a relationship in PET0 between liver SUV sub(mean) and SUV sub(max) with the stage, which was lower in those patients with advanced disease (r super(2)=0.1456 and p=0.0013 for SUV sub(mean) and r super(2)=0.1277 and p=0.0028 for SUV sub(max)). Conclusion: The results of our study suggest that liver super(18)F-FDG uptake is variable in patients with HL during the CHT treatment and the disease course and should be considered carefully when used to define the response to therapy in the interim PET in HL.</abstract><doi>10.1007/s00259-014-2703-0</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1619-7070 |
| ispartof | European journal of nuclear medicine and molecular imaging, 2014-06, Vol.41 (6), p.1123-1132 |
| issn | 1619-7070 1619-7089 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1524414455 |
| source | Springer Nature - Complete Springer Journals |
| title | Factors affecting intrapatient liver and mediastinal blood pool super(18)F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T18%3A09%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Factors%20affecting%20intrapatient%20liver%20and%20mediastinal%20blood%20pool%20super(18)F-FDG%20standardized%20uptake%20value%20changes%20during%20ABVD%20chemotherapy%20in%20Hodgkin's%20lymphoma&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=Chiaravalloti,%20Agostino&rft.date=2014-06-01&rft.volume=41&rft.issue=6&rft.spage=1123&rft.epage=1132&rft.pages=1123-1132&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-014-2703-0&rft_dat=%3Cproquest%3E1524414455%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1524414455&rft_id=info:pmid/&rfr_iscdi=true |